ZACKS·2025-10-28 15:08Core Viewpoint - Qiagen (QGEN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Qiagen's quarterly earnings is $0.58 per share, reflecting a year-over-year decrease of 1.7%, while revenues are projected to be $525.99 million, representing a 4.8% increase from the previous year [3]. - The earnings report is scheduled for release on November 4, and the stock may experience upward movement if the reported figures exceed expectations, whereas a miss could lead to a decline [2]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 0.67%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Qiagen is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.73%, which complicates the prediction of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, Qiagen met the expected earnings of $0.60 per share, resulting in no surprise [13]. - Over the last four quarters, the company has surpassed consensus EPS estimates in two instances [14]. Industry Context - Syndax Pharmaceuticals (SNDX), a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.74 per share for the same quarter, marking a year-over-year change of +24.5%, with revenues projected at $48.69 million, up 289.5% from the previous year [18]. - Despite a recent downward revision of 13.9% in the consensus EPS estimate for Syndax, it currently holds an Earnings ESP of +0.23%, although it has a Zacks Rank of 4 (Sell), making predictions of an earnings beat challenging [19][20].